CoChat

Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder: (Trial 144: A Randomized Controlled Study)

Open access
Weisler, Richard H., Nolen, Willem A., Neijber, Anders, Hellqvist, Åsa, Paulsson, Björn, Trial 144 Study Investigators · 2011 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record.

Abstract

Article Abstract Objective: Quetiapine, combined with lithium or divalproex, demonstrates efficacy in the maintenance treatment of bipolar I disorder. This study investigated the efficacy and safety of quetiapine monotherapy as maintenance treatment in bipolar I disorder compared with switching to placebo or lithium. Method: Patients aged ≥ 18 years with DSM-IV-diagnosed bipolar I disorder and a current or recent manic, depressive, or mixed episode received open-label quetiapine (300-800 mg/d) for 4-24 weeks. Patients achieving stabilization were randomized to continue quetiapine or to switch to placebo or lithium (0.6-1.2 mEq/L) for up to 104 weeks in a double-blind trial. Outcome measures included times to recurrence of any mood event (primary outcome measure), manic event, or depressive event. Safety assessments included adverse events and laboratory values. The study was terminated early after planned interim analysis provided positive results. The study was conducted between March 2005 and July 2007. Results: Of 2,438 patients starting open-label quetiapine, 1,226 (50.3%) were randomized to double-blind treatment, including 1,172 (95.6%) in the intent-to-treat population. Time to recurrence of any mood event was significantly longer for quetiapine versus placebo (hazard ratio = 0.29; 95% CI, 0.23-0.38; P < .0001) and for lithium versus placebo (HR = 0.46; 95% CI, 0.36-0.59; P < .0001). Quetiapine and lithium significantly increased time to recurrence of both manic events (quetiapine: HR = 0.29; 95% CI, 0.21-0.40; P < .0001; lithium: HR = 0.37; 95% CI, 0.27-0.53; P < .0001) and depressive events (quetiapine: HR = 0.30; 95% CI, 0.20-0.44; P < .0001; lithium: HR = 0.59; 95% CI, 0.42-0.84; P < .004) compared with placebo. Overall rates of adverse events were generally similar between treatment groups, and safety findings for quetiapine were consistent with its known profile. Conclusions: In patients stabilized during acute quetiapine treatment, continuation of quetiapine significantly increased time to recurrence of any mood, manic, or depressive event compared with switching to placebo. Switching to lithium was also more effective than placebo for the prevention of manic and depressive events. Trial Registration: clinicaltrials.gov Identifier: NCT00314184 J Clin Psychiatry © Copyright 2011 Physicians Postgraduate Press, Inc. Submitted: January 24, 2011; accepted July 28, 2011. Online ahead of print: October 18, 2011 (doi:10.4088/JCP.11m06878). Corresponding author: Richard H. Weisler, MD, Department of Psychiatry and Behavioral Science, Duke University Medical Center, Department of Psychiatry, University of North Carolina at Chapel Hill, 700 Spring Forest, Ste 125, Raleigh, NC 27609 (RWeisler@aol.com).

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.11m06878

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 169

Metadata

Authors
Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, Å., Paulsson, B., & Trial 144 Study Investigators
Affiliations
University of North Carolina at Chapel Hill (US)
Corresponding author
Weisler, Richard H.
Venue
The Journal of Clinical Psychiatry
Published
2011-11-15
Volume
72
Issue
11
Pages
1452-1464
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2034480582
Cited by
169
References
0
Citations by year
2026: 3 · 2025: 7 · 2024: 10 · 2023: 8 · 2022: 4 · 2021: 8 · 2020: 10 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 12 · 2015: 15 · 2014: 23 · 2013: 23 · 2012: 15
FWCI
13.33
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • Universidad Peruana Cayetano Heredia Institutional Repository (submittedVersion, cc-by-nc-nd)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
quetiapine, bipolar I disorder, maintenance therapy, lithium, mood stabilizers, relapse prevention, manic episodes, depressive episodes, drug switching, adverse events, atypical antipsychotics, lithium toxicity, divalproex, open-label extension, early trial termination
MeSH terms
Quetiapine Fumarate, Adult, Bipolar Disorder, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lithium, Male, Middle Aged, Placebos, Antipsychotic Agents, Proportional Hazards Models, Treatment Outcome, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder: (Trial 144: A Randomized Controlled Study). https://app.cochat.ai/papers/10.4088/jcp.11m06878
The paper
Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, Å., Paulsson, B., & Trial 144 Study Investigators. (2011). Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder: (Trial 144: A Randomized Controlled Study). The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11m06878

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.